Proxy Votes Now

Home › Funds › T. Rowe Price › T. Rowe Price Health Sciences Portfolio

T. Rowe Price Health Sciences Portfolio (QAAGZX) proxy voting record 2025-2026

Fund family: T. Rowe Price · Filed by T. Rowe Price Equity Series, Inc. (CIK 918294) · SEC series S000002083

Share classes and tickers: QAAGZX (C000005448), QAAHBX (C000005449)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,345 with, 27 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with T. Rowe Price as a whole

The same two figures as T. Rowe Price’s manager page (244,024 ballot items across 112 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsT. Rowe PriceItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.4%1,28093.7%208,710
Backed environmental and social shareholder proposals at US companiesn/a82.6%3,333

Where this fund voted differently from most T. Rowe Price funds

Each ballot item this fund voted is set against the votes of the other T. Rowe Price funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most T. Rowe Price funds on 11 items (1.1% of the 1,043 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost T. Rowe Price fundsMgmtResult
Shattuck Labs, Inc.2026-05-28To approve an amendment and restatement of the Company's 2020 Equity Incentive Plan.AgainstFOR — 8 of 8 T. Rowe Price fundsAgainstPassed (calculated), 80.2% support
Immatics N.V.2026-06-18Approve 2026 Stock Option and Incentive PlanAgainstFOR — 8 of 8 T. Rowe Price fundsAgainst—
Immatics N.V.2026-06-18Reelect A.L. Stone as Non-Executive Director IIIForAGAINST — 8 of 8 T. Rowe Price fundsFor—
Cytokinetics, Incorporated2026-05-272 wordings Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.WithholdFOR — 15 of 21 T. Rowe Price fundsAgainstPassed (calculated), 97.0% support
Molina Healthcare, Inc.2026-05-06To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAGAINST — 11 of 16 T. Rowe Price fundsForPassed (calculated), 52.8% support
MapLight Therapeutics, Inc.2026-06-23To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Martin BablerForWITHHOLD — 8 of 13 T. Rowe Price fundsFor—
Xenon Pharmaceuticals Inc.2026-06-02To approve the Corporation's 2026 Equity Incentive Plan;AgainstFOR — 7 of 11 T. Rowe Price fundsAgainstApproved, 68.0% support
Kodiak Sciences Inc.2026-06-02Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. BancroftForWITHHOLD — 8 of 14 T. Rowe Price fundsForElected, 78.7% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: David Schenkein, M.D.ForWITHHOLD — 8 of 14 T. Rowe Price fundsForElected, 73.5% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: Jennifer CookForWITHHOLD — 8 of 14 T. Rowe Price fundsForElected, 60.9% support
Dianthus Therapeutics, Inc.2026-05-21To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeForWITHHOLD — 8 of 15 T. Rowe Price fundsForPassed (calculated), 80.6% support

Download all 11 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 77.5% of this fund’s 1,372 such votes could be given a sector; the other 309 (22.5%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care997232.3%
Industrials4924.1%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections8070
Audit-related1590
Say-on-Pay1400
Compensation1072
Capital Structure840
Corporate Governance7416
Other Social Issues75
Shareholder Rights and Defenses71
Extraordinary Transactions40
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$114M102
Thermo Fisher Scientific Inc.May 20, 2026$39M130
argenx SENovember 18, 2025$37M10
UnitedHealth Group IncorporatedJune 1, 2026$31M121
Merck & Co., Inc.May 26, 2026$28M183
AbbVie Inc.May 8, 2026$27M81
argenx SEMay 6, 2026$26M120
Intuitive Surgical, Inc.April 30, 2026$24M130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
May 13, 2026Elevance Health, Inc.Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposalAgainstFor

Funds that vote the same way

These funds reported the same votes as T. Rowe Price Health Sciences Portfolio in the latest season, so they share this page:

Search this fund’s votes by company

1,392 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, T. Rowe Price Health Sciences Portfolio (QAAGZX) voted at 160 shareholder meetings of 156 companies, on 1,392 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals less often than T. Rowe Price's funds as a whole (92.4% against 93.7%). It voted differently from most T. Rowe Price funds on 11 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of T. Rowe Price’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.